NYSEAMERICAN:CANF - CAN-FITE BIOPHA/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.14 -0.02 (-1.72 %)
(As of 02/22/2019 06:11 AM ET)
Previous Close$1.16
Today's Range$1.13 - $1.16
52-Week Range$1.00 - $2.07
Volume61,600 shs
Average Volume203,506 shs
Market Capitalization$22.78 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. has a collaborative research agreement with the Icahn School of Medicine for therapeutic discovery of liver diseases. The company was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CANF
CUSIPN/A
Phone+972-3-9241114

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees7
Market Cap$22.78 million
Next Earnings Date3/22/2019 (Estimated)
OptionableOptionable

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) Frequently Asked Questions

What is CAN-FITE BIOPHA/S's stock symbol?

CAN-FITE BIOPHA/S trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."

How were CAN-FITE BIOPHA/S's earnings last quarter?

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) announced its quarterly earnings data on Wednesday, April, 8th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.05. View CAN-FITE BIOPHA/S's Earnings History.

When is CAN-FITE BIOPHA/S's next earnings date?

CAN-FITE BIOPHA/S is scheduled to release their next quarterly earnings announcement on Friday, March 22nd 2019. View Earnings Estimates for CAN-FITE BIOPHA/S.

What price target have analysts set for CANF?

2 Wall Street analysts have issued twelve-month price targets for CAN-FITE BIOPHA/S's stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate CAN-FITE BIOPHA/S's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 557.9% from the stock's current price. View Analyst Price Targets for CAN-FITE BIOPHA/S.

What is the consensus analysts' recommendation for CAN-FITE BIOPHA/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CAN-FITE BIOPHA/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CAN-FITE BIOPHA/S.

What are Wall Street analysts saying about CAN-FITE BIOPHA/S stock?

Here are some recent quotes from research analysts about CAN-FITE BIOPHA/S stock:
  • 1. According to Zacks Investment Research, "Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate is being developed for the treatment of liver diseases and its CF602 drug is being developed for the treatment of inflammation and sexual dysfunction. Can Fite Biopharma Ltd. is based in Petach Tikva, Israel. " (2/5/2019)
  • 2. HC Wainwright analysts commented, "We also note that Namodenoson has both Track status in the hepatocellular carcinoma (HCC) indication. Namodenoson could be approved based on this study. The trial is a Phase 2 study, but given the unmet medical need, if the data is strong enough, it could be used as a registrational study. For this reason and for ethical reasons, management has been advised not to alter the original study design (statistical plan)." (10/31/2018)
  • 3. Maxim Group analysts commented, "While we anticipated CanFite would need to raise capital we did not anticipate the added dilution announced in today’s raise and the potential impact of raising too little capital which sets up additional dilution." (3/9/2018)

Has CAN-FITE BIOPHA/S been receiving favorable news coverage?

News headlines about CANF stock have been trending somewhat positive recently, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CAN-FITE BIOPHA/S earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Are investors shorting CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 435,916 shares, a decline of 20.1% from the January 15th total of 545,631 shares. Based on an average trading volume of 324,346 shares, the days-to-cover ratio is currently 1.3 days. View CAN-FITE BIOPHA/S's Current Options Chain.

Who are some of CAN-FITE BIOPHA/S's key competitors?

What other stocks do shareholders of CAN-FITE BIOPHA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CAN-FITE BIOPHA/S investors own include BIOLINERX LTD/S (BLRX), TransEnterix (TRXC), AEterna Zentaris (AEZS), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Opko Health (OPK), TherapeuticsMD (TXMD), Athersys (ATHX), Cancer Genetics (CGIX) and Amicus Therapeutics (FOLD).

Who are CAN-FITE BIOPHA/S's key executives?

CAN-FITE BIOPHA/S's management team includes the folowing people:
  • Dr. Ilan Cohn, Co-Founder & Chairman (Age 65)
  • Prof. Pnina Fishman, Scientific Founder, CEO & Director (Age 71)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 55)
  • Dr. Sari Fishman Ph.D., VP of Bus. Devel. (Age 47)
  • Dr. Vibeke Strand M.D., FACP, FACR (USA), Sr. Clinical Advisor

How do I buy shares of CAN-FITE BIOPHA/S?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CAN-FITE BIOPHA/S's stock price today?

One share of CANF stock can currently be purchased for approximately $1.14.

How big of a company is CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S has a market capitalization of $22.78 million. CAN-FITE BIOPHA/S employs 7 workers across the globe.

What is CAN-FITE BIOPHA/S's official website?

The official website for CAN-FITE BIOPHA/S is http://www.canfite.co.il.

How can I contact CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company can be reached via phone at +972-3-9241114.


MarketBeat Community Rating for CAN-FITE BIOPHA/S (NYSEAMERICAN CANF)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  221
MarketBeat's community ratings are surveys of what our community members think about CAN-FITE BIOPHA/S and other stocks. Vote "Outperform" if you believe CANF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CANF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel